Immunobiology of Cancer
Stopped early
Conditions studied: Neoplasms
In brief
To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.
Key facts
- Study ID
- NCT00767533
- Run by
- Stanford University
- People needed
- 84
- Starts
- 2008-10-01
- Expected to finish
- 2011-10-01
- Last updated by the study team
- 2016-07-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.